Cancer Immunotherapy: A promising platform for predicting toxicity
Organ-on-chip approaches could help researchers to better predict the toxicity of cancer immunotherapy drugs.
- Lausanne University Hospital, Switzerland
Killing cancer cells can be done directly or by harnessing the immune system through an approach called cancer immunotherapy (Robert, 2020). Indeed, over the past decade, most of the advances in oncology have involved boosting immune cells to destroy tumor cells. Some of these treatments have resulted in impressive improvements in survival, bringing the possibility of a cure closer for some patients (Robert et al., 2018). This is a big milestone in oncology.
Despite these advances, immunotherapies can be associated with toxicity, which forces the treatment to be stopped: if immune cells become too activated, they can mistakenly recognize and destroy healthy tissues. This can lead, for example, to rashes, hepatitis or colitis depending on whether the skin, liver or gut are attacked (Marin-Acevedo et al., 2019).
A big challenge in oncology is therefore to predict which new immunotherapy drugs are going to be too harmful for patients. This is usually examined in animal models, but since their immune systems differ from the human immune system, it can be difficult to reliably predict toxicity (Zschaler et al., 2014). Now, in eLife, Nikolce Gjorevski (Roche), Lauriane Cabon (Roche) and colleagues – including Jordan Kerns and Chaitra Belgur of Emulate Inc in Boston as joint first authors – report how an in vitro model can help bypass this problem for T cell bispecific antibodies immunotherapy (Kerns et al., 2021).
T cell bispecific antibodies (or TCBs) can recognise and bind to ‘antigen’ proteins present on the surface of tumors, as well as receptors displayed by immune ‘T cells’: by bringing the two types of cells closer, this process helps to activate T cells and allows them to kill their targets. However, the antigens that TCBs bind to are not always exclusive to cancer cells. Recognition of non-cancer cells which share antigens with tumors – known as the on-target, off-tumor effect – can lead to normal cells being damaged (Labrijn et al., 2019; Figure 1). Predicting which TCBs under clinical development will cause such undesired toxicity represents an important challenge in oncology.
Figure 1
Testing drug toxicity using an organ-on-chip platform.
Administering TCBs to an organ-on-chip platform (such as a model of the lung or intestine) allows the antibodies (Y-shaped structures) to recognize antigens (shown in yellow and blue) present in both healthy epithelial and cancerous cells. This brings T cells close to their targets and also activates them, which can lead to healthy cells being damaged (as assessed by measuring cell death and inflammation levels). This model is able to partially reproduce toxicity observed in animals and humans.
Image credit: Image was prepared with Servier Medical Art (CC BY 3.0).
To address this issue, Kerns et al. first took advantage of a lung-on-chip model (Huh et al., 2010) – a system grown under conditions mimicking those found in the body – to predict toxicity to TCBs. This ‘mini-organ’ was exposed to a TCB that recognises an antigen present in ovarian, lung and breast cancer cells, but which can also be expressed, at lower levels, in healthy lung cells. This manipulation led to healthy cells being damaged in the lung-on-chip model, which was then used to determine which TCB dose could kill tumors while sparing normal lung cells. This dose was then administered to mouse models, whose lungs remained undamaged. This demonstrates that the lung-on-chip was able to efficiently predict toxicity in these animals.
Kerns et al. then used an intestine-on-chip model to test a TCB which targets an antigen present on both colon cancer and normal intestine cells. Healthy cells survived the treatment but signs of toxicity emerged that could mimick side-effects that commonly occur in patients, such as increased inflammation.
Using an organ-on-chip model to test TCBs therefore has two main advantages. First, it reproduces toxicity observed in vivo, and can help to determine which doses are effective while remaining safe for normal cells. Second, it serves to predict toxicity before patients are administered with newly-developed TCBs, filling the gap between animal and human studies for drugs that are yet to be clinically tested. Organ-on-chip models could therefore make drug development more efficient by helping to screen out toxic TCBs before they reach cancer patients.
References
-
Bispecific antibodies: a mechanistic review of the pipelineNature Reviews Drug Discovery 18:585–608.https://doi.org/10.1038/s41573-019-0028-1
-
Immune checkpoint inhibitor toxicitiesMayo Clinic Proceedings 94:1321–1329.https://doi.org/10.1016/j.mayocp.2019.03.012
-
Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaJournal of Clinical Oncology 36:1668–1674.https://doi.org/10.1200/JCO.2017.75.6270
-
A decade of immune-checkpoint inhibitors in cancer therapyNature Communications 11:3801.https://doi.org/10.1038/s41467-020-17670-y
-
Differences in innate immune response between man and mouseCritical Reviews in Immunology 34:433–454.https://doi.org/10.1615/CritRevImmunol.2014011600
Article and author information
Author details
Maria Ochoa de Olza
Publication history
Copyright
© 2021, Ochoa de Olza
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 900
- views
-
- 65
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cancer Immunotherapy: A promising platform for predicting toxicity
eLife 10:e73191.
https://doi.org/10.7554/eLife.73191
Further reading
-
- Cancer Biology
Glioblastomas are aggressive brain tumors with dismal prognosis. One of the main bottlenecks for developing more effective therapies for glioblastoma stems from their histologic and molecular heterogeneity, leading to distinct tumor microenvironments and disease phenotypes. Effectively characterizing these features would improve the clinical management of glioblastoma. Glucose flux rates through glycolysis and mitochondrial oxidation have been recently shown to quantitatively depict glioblastoma proliferation in mouse models (GL261 and CT2A tumors) using dynamic glucose-enhanced (DGE) deuterium spectroscopy. However, the spatial features of tumor microenvironment phenotypes remain hitherto unresolved. Here, we develop a DGE Deuterium Metabolic Imaging (DMI) approach for profiling tumor microenvironments through glucose conversion kinetics. Using a multimodal combination of tumor mouse models, novel strategies for spectroscopic imaging and noise attenuation, and histopathological correlations, we show that tumor lactate turnover mirrors phenotype differences between GL261 and CT2A mouse glioblastoma, whereas recycling of the peritumoral glutamate-glutamine pool is a potential marker of invasion capacity in pooled cohorts, linked to secondary brain lesions. These findings were validated by histopathological characterization of each tumor, including cell density and proliferation, peritumoral invasion and distant migration, and immune cell infiltration. Our study bodes well for precision neuro-oncology, highlighting the importance of mapping glucose flux rates to better understand the metabolic heterogeneity of glioblastoma and its links to disease phenotypes.
-
- Cancer Biology
- Medicine
A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.
